Welcome to our dedicated page for MiniMed Group SEC filings (Ticker: MMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MiniMed Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MiniMed Group's regulatory disclosures and financial reporting.
MiniMed Group, Inc. (MMED) reported strong top-line growth for the quarter ended July 31, 2026, with net sales of $843 million, up 16.6% from $723 million, driven by pumps, consumables, and especially CGM products and aided by an extra fiscal week. Organic revenue grew 15.8%. Gross profit rose to $465 million, though gross margin declined to 55.1% from 56.6% due to higher mix of lower-margin Simplera CGM sensors. Operating income improved to $5 million from a $13 million loss, and net income was roughly break-even versus a $16 million loss a year earlier; Adjusted EBITDA increased to $83 million from $50 million, reflecting leverage on higher volume and lower litigation expense.
New pump placements reached 34,000 versus 32,000, and the Global CGM Attachment Rate increased to 69% from 64%, supporting recurring revenue. Cash and equivalents were $207 million with no borrowings on a $500 million revolving credit facility, though operations used $49 million of cash. The company highlights ongoing separation and transition costs from Medtronic, pricing pressure in CGM, significant diabetes pump retainer ring litigation exposure, and a $157 million royalty obligation to Blackstone tied to MiniMed Flex as important factors for future profitability and cash flows.
MiniMed Group, Inc. (MMED) reported strong first-quarter fiscal 2027 results for the period ended July 31, 2026, with worldwide net sales of $843 million, up 16.6% as reported and 15.8% on an organic basis. U.S. net sales were $240 million, up 13.1%, while international net sales were $603 million, up 18.1% as reported and 16.9% organic. Results included an estimated 4%–6% benefit from an extra fiscal week, with underlying low double-digit organic growth.
By product, pump revenue rose to $144 million (+21.5%), consumables to $261 million (+13.8%), and CGM to $431 million (+19.9%). Operating income improved to $5 million from a $13 million loss, and net income attributable to the company was approximately breakeven versus a $19 million loss a year earlier. Worldwide new pumps sold were about 34,000, up 7.7%, and the CGM attachment rate reached 69%, up roughly 100 bps sequentially.
MiniMed highlighted rapid adoption of MiniMed Flex™ in the U.S. and significant pipeline progress, including FDA submission of the MiniMed Fit™ patch pump, CE Mark for MiniMed Flex™, completion of enrollment in the U.S. pivotal trial for the Vivera™ fully-closed loop algorithm, and IDE approval for a next-generation extended-wear sensor. For fiscal 2027, MiniMed raised its organic revenue growth outlook to approximately 10.5% (including a 1.0%–1.5% extra-week benefit) from about 10% and reaffirmed its target adjusted EBITDA margin of roughly 16%.
MiniMed Group, Inc. (MMED) is soliciting proxies for its virtual-only 2026 annual meeting of stockholders on October 9, 2026 at 9:00 a.m. Pacific Time, with a record date of August 11, 2026. Stockholders will vote on four proposals: election of four Class I directors, ratification of the independent registered public accounting firm, an advisory vote to approve named executive officer compensation, and an advisory vote on the frequency of say-on-pay votes.
MiniMed, a standalone diabetes-focused medtech company separated from Medtronic plc in March 2026, remains majority-owned by Medtronic, which continues to hold approximately 90% of the common stock and treat MiniMed as a Nasdaq “controlled company.” The proxy details a staggered three-class, 11-member board, the use of controlled-company exemptions, director independence determinations, director and committee structure, and extensive ongoing agreements with Medtronic, including the Separation Agreement, tax, employee matters, transition services, trademark, and cross-license arrangements.
MiniMed Group, Inc. disclosed that Courtney Nelson Wills, Senior Vice President, General Counsel and Corporate Secretary, has decided to resign from her position. She notified the company on July 30, 2026, and her resignation will be effective September 25, 2026 following an 8‑week transition period.
The company states that Ms. Nelson Wills is leaving for personal reasons, having accepted a role outside the medical device industry, and that her departure is not due to any disagreement with MiniMed. MiniMed is conducting a search for a successor and emphasizes its commitment to maintaining strong legal, governance, and compliance oversight during the transition. The disclosure also includes standard forward‑looking statements language referencing risks and uncertainties described in its SEC reports.
MiniMed Group, Inc. executive Courtney Nelson, SVP, General Counsel and Corporate Secretary, reported a tax-withholding disposition of 1,762 shares of common stock on July 31, 2026, at $18.15 per share. The shares were withheld to cover income taxes on vesting RSUs, leaving 136,384 shares held directly, including shares issuable from RSUs.
MiniMed Group, Inc. executive Dianaty Ali, EVP Ch. Prod. & Tech Officer, reported a tax-withholding disposition of 8,012 shares of Common Stock on July 31, 2026, at $18.15 per share to cover income tax obligations from RSU vesting. After this transaction, Ali directly holds 315,158 shares, including shares to be issued upon RSU vesting.
Dallara Que, Chief Executive Officer of MiniMed Group, Inc., reported a tax-withholding disposition of 31,350 shares of Common Stock on July 31, 2026 at $18.15 per share. The shares were withheld by the company to satisfy RSU-related tax obligations. Que now directly holds 884,749 shares, including shares issuable upon RSU vesting.
MiniMed Group, Inc. EVP and Chief Financial Officer Chad Spooner reported a tax-withholding disposition of 23,301 shares of Common Stock on July 28, 2026. These shares were withheld by MiniMed Group to satisfy income tax withholding and remittance obligations tied to vesting Restricted Stock Units. After this withholding, Spooner directly holds 362,707 shares of Common Stock, including shares to be issued upon the vesting of one or more RSUs.
MiniMed Group, Inc. executive Chandrasena Gillian, SVP and Chief HR Officer, reported a tax-withholding disposition of 2,099 shares of Common Stock on 2026-07-28 at $17.67 per share. The shares were withheld by the company to satisfy income tax obligations related to RSU vesting, leaving 172,745 shares owned directly, including shares to be issued upon the vesting of one or more RSUs.